Prof. Xudong Wei 魏旭东
Chief Physician, Professor
Department of Hematology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Treatment of leukemia, lymphoma, myeloma, and other blood disorders. Research on molecular prognosis and individualized therapy for acute myeloid leukemia and lymphoma.
Dr. Wei is Director of Hematology at Henan Cancer Hospital, holding a PhD from Peking University and completing postdoctoral work at the University of Colorado. A recipient of the State Council special allowance, Dr. Wei developed the CHAG regimen for refractory acute myeloid leukemia and the non-chemotherapy Ganbaisha regimen for refractory lymphoma and leukemia.
Professional roles
- Member, Hematologic Oncology Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Hematoimmunology Professional Committee, Chinese Society for Immunology
- Editorial Board Member, Chinese Journal of Hematology
- Editorial Board Member, Journal of Leukemia & Lymphoma
Name order: in Chinese the family name comes first (Wei Xudong). Papers usually list the name as Xudong Wei or Wei X.
Selected publications
122 papers on PubMed matched by name and affiliation; 39 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cytotherapy, 2026 (senior author): Clinical analysis of fecal microbiota transplantation for refractory acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a five-year retrospective study. PubMed 41689915
- Front Oncol, 2026 (senior author): Case Report: Safety analysis of blinatumomab consolidation therapy in two cases of acute B-cell lymphoblastic leukemia in complete remission complicated with immune effector cell-associated neurotoxicity syndrome. PubMed 41809830
- Front Oncol, 2025 (senior author): Avapritinib in the treatment of systemic mastocytosis with associated acute myeloid leukemia after poor graft function following allogeneic hematopoietic stem cell transplantation: a case study and review of the literature. PubMed 41473436
- Leuk Res, 2025 (senior author): Multicenter retrospective analysis of the short-term efficacy and safety of the VAH regimen in the treatment of acute myeloid leukemia. PubMed 41151207
- Eur J Clin Microbiol Infect Dis, 2025 (senior author): Efficacy and safety of contezolid in the treatment of Gram-positive bacterial infections in patients with hematological malignancies: a retrospective study. PubMed 41023352
- Front Oncol, 2025 (senior author): Retrospective analysis of sorafenib combined with interferon α-1b, interleukin-2, and thalidomide as maintenance therapy in FLT3-ITD-positive acute myeloid leukemia. PubMed 41312168
- Front Oncol, 2025 (senior author): Case Report: Venetoclax combined with hypomethylating agents for the treatment of newly diagnosed with mixed-phenotype acute leukemia and a literature review. PubMed 41220934
- PLoS Negl Trop Dis, 2025 (senior author): Hematological diseases-related mucormycosis: A retrospective single center study. PubMed 41004493
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion